glp 1 agonist mechanism of action Frontiers Mechanism of action for GLP-1R

Gastroenterology 86(2):274280 Ritzel R, Orskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers

The frequency of these side effects is fairly low, reported in less than 10% of recipients

Both note the effect is small and fades over time

BPC 157 therapy can counteract the consequences of dopamine neurons destruction in the substantia nigra (neurotoxin MPTP) [69], dopamine vesicle depletion (reserpine) [69], dopamine receptors blockade (neuroleptics) [68,70], dopamine over-release and re-uptake inhibition (amphetamine